Immunological safety assessment of intravenous injection of rat embryonic proteome extract for in vivo regenerative therapies

Abstract

Author(s): Siva Rama Prasad Darsi, Siva Kumar Kandula, Kala Kumar. Bharani, Satyanarayana Swamy Cheekatla, Adi Reddy Kamireddy, Sreedhar. Surampudi, Sujesh Kumar Darsi, Vishnu Vardhan Reddy Arrabottu, Anilkumar Banothu

The branch of regenerative medicine has been advancing in recent years, thanks to milestone discoveries in stem cell biology and tissue engineering; now driven paradigm shifts in the embryonic molecular therapy of traumatic injuries, organ failure, cancer, degenerative, and ischemic diseases. Mother's womb is the manufacturing unit of all tissues and organs, and thus embryo is a plethora of tissue differentiation, organ generation, and growth factors. Embryonic molecules of the embryo mediates significant in vivo replenishment of lost and/or dysfunctional tissue and organs. Simultaneously, it is advancing by overcoming major limitations like tumorigenecity, heterogeneity, and immunogenicity. Present study was focused on immune response through intravenous injection of 14th, 16^th and 19^th day embryonic proteome extract. Methods: Isolation of embryonic proteome for 14^th, 16^th , and 19^th embryonic days of 3 SD rats were injected for the assessment of serum CRP and IL-6 Results: EPE injected rats were compared with control. Both CRP and IL-6 has shown no significant difference between the control and treated and were found within normal limits (p< 0.05). In conclusion, present study has confirmed that embryonic proteome extract are safe without immunological rejections and thus can be used for the in vivo regenerative therapies.

Share this article